ES2072647T3 - Composiciones que contienen sales de ranitidina/carboxilato de bismuto. - Google Patents

Composiciones que contienen sales de ranitidina/carboxilato de bismuto.

Info

Publication number
ES2072647T3
ES2072647T3 ES92103741T ES92103741T ES2072647T3 ES 2072647 T3 ES2072647 T3 ES 2072647T3 ES 92103741 T ES92103741 T ES 92103741T ES 92103741 T ES92103741 T ES 92103741T ES 2072647 T3 ES2072647 T3 ES 2072647T3
Authority
ES
Spain
Prior art keywords
acid
bismute
compositions containing
ranitidine
carboxylate salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92103741T
Other languages
English (en)
Inventor
Stephen John Douglas
Colin Roy Heppenstall
Norman Richard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2072647T3 publication Critical patent/ES2072647T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL INVENTO SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE DOSIS DE UNIDAD SOLIDA ADAPTADA PARA ADMINISTRACION ORAL, QUE COMPRENDE UNA SAL FORMADA ENTRE RANITIDINA Y UN COMPLEJO DE BISMUTO CON UN ACIDO CARBOXILICO SELECCIONADO DE ACIDO TARTARICO Y UN ACIDO CITRICO CONJUNTAMENTE CON UNA SAL ALCALINA. POR EJEMPLO LA COMPOSICION TIENE FORMA DE TABLETA Y COMPRENDE CARBONATO DE SODIO Y CITRATO DE BISMUTO RANITIDINA. LA COMPOSICION MUESTRA DESINTEGRACION Y/O DISOLUCION MEJORADAS.
ES92103741T 1990-09-11 1992-03-05 Composiciones que contienen sales de ranitidina/carboxilato de bismuto. Expired - Lifetime ES2072647T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909019875A GB9019875D0 (en) 1990-09-11 1990-09-11 Pharmaceutical compositions
NO920408A NO179694C (no) 1990-09-11 1992-01-30 Farmasöytiske preparater inneholdende ranitidinderivater
PCT/EP1992/000498 WO1993017679A1 (en) 1990-09-11 1992-03-05 Compositions containing ranitidine/bismuth carboxylates salts

Publications (1)

Publication Number Publication Date
ES2072647T3 true ES2072647T3 (es) 1995-07-16

Family

ID=47884627

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92103741T Expired - Lifetime ES2072647T3 (es) 1990-09-11 1992-03-05 Composiciones que contienen sales de ranitidina/carboxilato de bismuto.

Country Status (33)

Country Link
US (1) US5456925A (es)
EP (1) EP0558779B1 (es)
JP (1) JPH0692849A (es)
KR (1) KR100196308B1 (es)
AT (2) AT405134B (es)
AU (2) AU640816B2 (es)
BE (1) BE1005115A5 (es)
BG (1) BG61931B1 (es)
CA (1) CA2050970C (es)
CH (1) CH683068A5 (es)
CY (1) CY1988A (es)
DE (2) DE4130061A1 (es)
DK (1) DK159191A (es)
ES (1) ES2072647T3 (es)
FI (1) FI944047A (es)
FR (1) FR2666508B1 (es)
GB (2) GB9019875D0 (es)
HK (1) HK60894A (es)
HU (1) HU211846A9 (es)
IE (1) IE65049B1 (es)
IL (1) IL99428A (es)
IT (1) IT1249696B (es)
MX (1) MX9101009A (es)
NL (1) NL194907C (es)
NO (1) NO179694C (es)
NZ (1) NZ239731A (es)
OA (1) OA10093A (es)
RO (1) RO112084B1 (es)
RU (1) RU2108097C1 (es)
SE (1) SE509694C2 (es)
SK (1) SK279591B6 (es)
WO (1) WO1993017679A1 (es)
ZA (1) ZA917176B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
HUP9900428A2 (hu) * 1995-01-26 1999-06-28 Nycomed Imaging A/S Bizmutvegyületek, ezeket tartalmazó diagnosztikai kontrasztanyag, ennek alkalmazása és ezt tartalmazó gyógyászati készítmény
RU2385155C2 (ru) * 1998-08-18 2010-03-27 Федеральное Государственное Унитарное Предприятие Государственный Научно-Исследовательский Институт "Биоэффект" (Фгуп Гнии "Биоэффект") Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения
EP1104673A1 (en) * 1999-11-30 2001-06-06 Bayer Classics A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2010011522A1 (en) 2008-07-21 2010-01-28 Albemarle Corporation High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
US20230218663A1 (en) * 2020-06-01 2023-07-13 The University Of Hong Kong Compositions and methods for treating a sars-cov-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608257A (en) * 1984-01-03 1986-08-26 Board Of Regents For Oklahoma State University Composition and method for treating heat stress
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
CH679582A5 (es) * 1988-07-18 1992-03-13 Glaxo Group Ltd
EP0363502B1 (de) * 1988-10-08 1991-09-25 Dr. R. Pfleger Chemische Fabrik Gmbh Flüssiges, wismuthaltiges Arzneipräparat, Verfahren zum Herstellen desselben und seine Verwendung
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ITRM910673A1 (it) 1993-03-10
FR2666508A1 (fr) 1992-03-13
ZA917176B (en) 1992-06-24
GB9019875D0 (en) 1990-10-24
SK106094A3 (en) 1995-02-08
FR2666508B1 (fr) 1994-02-18
NO179694B (no) 1996-08-26
IL99428A (en) 1996-06-18
GB2248185A (en) 1992-04-01
MX9101009A (es) 1992-05-04
IL99428A0 (en) 1992-08-18
CA2050970C (en) 2002-11-19
AU640816B2 (en) 1993-09-02
AU8375791A (en) 1992-03-19
RO112084B1 (ro) 1997-05-30
AU1334792A (en) 1993-10-05
FI944047A0 (fi) 1994-09-02
ATE122883T1 (de) 1995-06-15
GB9119284D0 (en) 1991-10-23
FI944047A (fi) 1994-09-02
IE913191A1 (en) 1992-04-22
KR920005984A (ko) 1992-04-27
NO179694C (no) 1996-12-04
KR100196308B1 (ko) 1999-06-15
AT405134B (de) 1999-05-25
BE1005115A5 (fr) 1993-04-27
RU2108097C1 (ru) 1998-04-10
CH683068A5 (fr) 1994-01-14
HU211846A9 (en) 1995-12-28
SE9102604D0 (sv) 1991-09-10
OA10093A (en) 1996-12-18
HK60894A (en) 1994-07-08
NL194907C (nl) 2003-07-04
IT1249696B (it) 1995-03-09
CY1988A (en) 1997-09-05
JPH0692849A (ja) 1994-04-05
US5456925A (en) 1995-10-10
SK279591B6 (sk) 1999-01-11
DE4130061A1 (de) 1992-03-12
GB2248185B (en) 1994-02-02
DE69202696D1 (de) 1995-06-29
EP0558779B1 (en) 1995-05-24
DK159191A (da) 1992-03-12
NL194907B (nl) 2003-03-03
SE9102604L (sv) 1992-03-12
SE509694C2 (sv) 1999-02-22
IE65049B1 (en) 1995-10-04
NZ239731A (en) 1993-10-26
NL9101533A (nl) 1992-04-01
DK159191D0 (da) 1991-09-10
ATA180191A (de) 1998-10-15
WO1993017679A1 (en) 1993-09-16
NO920408D0 (no) 1992-01-30
NO920408L (no) 1993-08-02
ITRM910673A0 (it) 1991-09-10
BG99021A (bg) 1995-06-30
CA2050970A1 (en) 1992-03-12
BG61931B1 (bg) 1998-10-30
EP0558779A1 (en) 1993-09-08

Similar Documents

Publication Publication Date Title
ES2072647T3 (es) Composiciones que contienen sales de ranitidina/carboxilato de bismuto.
PE20010952A1 (es) Composicion para dosis oral de liberacion extendida
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
AR017512A1 (es) Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
FI895342A0 (fi) Ibuprofen-brusprodukter.
ATE158504T1 (de) Brausemischungen enthaltend ibuprofen und verfahren
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
CO5540295A2 (es) Comprimido para tragar que comprende paracetamol
ES2143481T3 (es) Comprimido de valproato de sodio de liberacion lenta.
PE68199A1 (es) Composicion farmaceutica de residencia gastrica
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
ES531346A0 (es) Procedimiento para producir una tableta de administracion oral de liberacion controlada, independiente del ph
GB1475861A (en) Pharmaceutical composition
ATE45090T1 (de) Pharmazeutische zusammensetzung in oralen darreichungsformen.
GB1357813A (en) Effervescent composition for the treatment of heart diseases
GB191010062A (en) Composition for Arresting and Preventing the Decay of Teeth.
UY23397A1 (es) Composicion y metodo de pro-droga de 5-fluorouracilo topica
ZA824649B (en) New optically active dipeptides, process for their preparation and pharmaceutical products containing these compounds
CU21980A1 (es) Composicion mineralizante dental y su forma farmaceutica
GB1266356A (es)
ES8303915A1 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".
GB1454390A (en) Nasal decongestants
GB884576A (en) Pharmaceutical compositions comprising an alkylamino substituted barbituric acid and salts thereof
GT199800053A (es) Composiciones farmaceuticas paraadministracionoraldeln-piperidino-5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metilpirazolo-3-carboxamida, de sus salesy desussolvatos.
KR790000319B1 (en) Process of manufacturing 2,4-diamino-pyrimidine with a sulphonamide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 558779

Country of ref document: ES